Legal Representation
Attorney
Enshan Hong
USPTO Deadlines
Next Deadline
1275 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-01-24)
Due Date
January 24, 2029
Grace Period Ends
July 24, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
17 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 24, 2023 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jan 24, 2023 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Nov 8, 2022 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Nov 8, 2022 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Oct 19, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Oct 5, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Oct 5, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 5, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Oct 5, 2022 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Oct 5, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Oct 4, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 1, 2022 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Sep 1, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Sep 1, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Sep 1, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 5, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jan 3, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific research in the field of genetics and genetic engineering; Scientific research consulting in the field of molecular biology, biotechnology, pharmaceutics, immunology and oncology, bacteriology, medical diagnostics and therapy using molecular biological, genetic engineering and biotechnological methods, and scientific research related to screening for pharmaceutically active compounds; Medical and scientific research in the field of molecular biology, biotechnology, pharmaceutics, immunology and oncology, bacteriology, medical diagnostics and therapy using molecular biological, genetic engineering and biotechnological methods, and scientific research related to screening for pharmaceutically active compounds; Scientific research and development; Scientific research and development of diagnostic methods and test processes; Scientific research and development related to technical planning and conducting of projects in the field of the supplying of medicines; Scientific consultancy services in the field of research and development of therapies and medical preparations; Provision of scientific expertise in the nature of scientific study and research in the field of medicine; Scientific research and development for medical and veterinary purposes; Medical and scientific research in the field of treatment of proliferating diseases, cancers, infectious diseases, autoimmune diseases, and neurodegenerative disease, metabolic diseases; Providing medical and scientific research information, consultancy, and advisory services in the fields of treatment of proliferating diseases, cancers, infectious diseases, autoimmune diseases, and neurodegenerative disease; Compiling data for medical and scientific research, clinical trials, and drug admission
First Use Anywhere:
May 10, 2021
First Use in Commerce:
May 10, 2021
Additional Information
Design Mark
The mark consists of stylized wording "REVIR".
Classification
International Classes
042